SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q4 results 2026: BHEL to Paytm among firms to declare Q4 earnings next week

… Fincorp 11 Ajanta Pharma 12 Emcure Pharmaceuticals 13 Aadhar Housing … Kriti Nutrients 46 Jenburkt Pharma 47 Kriti Industries (India) … Coast Hotels 61 Sandu Pharmaceuticals 62 Premier Energy and … STL Networks 39 Shukra Pharmaceuticals 40 Alldigi Tech 41 …

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka

India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging among millions needing obesity management. Broader specialist adoption and a growing prescriber base are fueling this expansion, promising substantial market growth.

India’s Cheap Ozempic Moment Is Here: Ozempic Prices Set to Drop to ₹3,000 as Semaglutide Goes Off-Patent in India

… in the highly successful weight-loss drugs called “Ozempic” and “Wegovy” developed … such as Mankind Pharma Ltd., Ajanta Pharma Ltd., Sun Pharmaceutical Industries Ltd. and … nearly 20% of all generic drugs available globally. The most significant impact …

Raja Venkatraman, MarketSmith India recommends five stocks for 16 March

On March 13, Indian stock indices Sensex and Nifty 50 faced continued selling pressure due to rising crude oil prices and global economic concerns. GIFT Nifty today suggests a mildly positive start, with several stocks recommended for buying, including Ajanta Pharma and Power Grid Corporation.

Everstone to sell stake in Restaurant Brands Asia – report

The family office of the founders of Ajanta Pharma in India may inject up to Rs8bn ($88m) into RBA.

Everstone to sell entire stake in India's Burger King operator Restaurant Brands Asia, sources say

Private equity firm Everstone is set to exit Restaurant Brands Asia, the franchisee for Burger King in India and Indonesia. The firm will sell its entire 11.26% stake. The Ajanta Pharma family office is poised to become the new strategic investor. This move could see the family office injecting significant funds and potentially acquiring a majority stake in the company.

India’s Ajanta Pharma eyes Irish manufacturing base

Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.

Biocon to supply semaglutide to Ajanta for marketing in 26 countries

Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically integrated drug product, semaglutide, used to improve glycemic control in adults with type-2 diabetes.

Indian equity benchmarks end flat in thin year-end trade; IT losses weigh

India’s equity benchmarks closed little changed on Wednesday in a subdued session marked by thin year-end volumes, with losses in information technology stocks weighing on sentiment. The Nifty 50 fell 0.13% to 26,142.1, while the BSE Sensex shed 0.14% to 85,408.7. Fifteen of the 16 major sectors declined. Small-caps rose 0.3%, while mid-caps fell 0.6%. Analysts said thin year-end trading kept volatility in check, with global volumes typically light ahead of the Christmas and New Year holidays. Indian markets will be closed on Thursday for Christmas. Investors are awaiting further cues, including a potential India-U.S. trade deal and October-December earnings, for a directional trade in the market. Motilal Oswal Financial Services said the earnings revision trends in the past four months have beaten its expectations. “The backdrop for earnings has improved vs last year, engineered by a series of stimulative fiscal and monetary measures,” the brokerage firm said. IT stocks fell 0.5% on the day after U.S.

Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The firm offers branded generics that serve a range of therapeutic segments such as antibiotic, anti-malarial, anti-diabetic, cardiology, gynecology, orthopedics, pediatric, respiratory, and general health. It operates through the following geographical segments: India, Africa, Asia, and USA. The company was founded by Purushottam Bhagwand Agrawal in 1973 and is headquartered in Mumbai, India.

Ajanta Pharma Ltd.

Tariff Jitters, RBI’s Pause Drag Nifty Below 24,600; Pharma, Tech Stocks Sink, NSDL Soars 17% On Debut

Equity

Neutral Sentiment

Indian equity markets ended lower on Wednesday as tariff jitters weighed on investor sentiment amid threats of ‘higher tariffs’ from US President Donald Trump. Trade tensions have been rising between the two nations over their trade ties with Russia. The Nifty index ended below the 24,600 mark.The Reserve Bank of India maintained the status quo on rates in its August review, in line with the market expectations. However, it has revised the inflation forecast for FY26 lower to 3.1%.&nbsp;On Wednesday, the Sensex closed 166 points lower at 80,543, while the&nbsp;<a href="https://stocktwits.com/symbol/NIFTY50.NSE">Nifty 50</a> ended 75 points lower at 24,574. Broader markets too underperformed, with the Nifty Midcap index ending 0.8% lower and the Smallcap index falling 1.1%.&nbsp;And the retail investor sentiment surrounding the Nifty 50 moved from ‘neutral’ to ‘bullish’ by market close on Stocktwits, amid ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:818/107;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_153328_png_056b0af116.webp" alt="Screenshot 2025-08-06 153328.png" width="818" height="107"><figcaption>Nifty sentiment and message volume on Aug 6 as of 4:00 pm IST. | source: Stocktwits</figcaption></figure>Stock MovesSectorally, barring PSU banks, the rest of the indices ended in the red, led by declines in pharma (-2%) and technology (-1.7%).Pharma stocks took a knock on the potential tariff hike to 250% on drug imports. Ajanta Pharma, IPCA Labs, Sun Pharma, Alkem Labs, and Zydus Life fell nearly 3%.&nbsp;Real estate stocks fell after RBI held rates steady: Anant Raj (-3%), Godrej Properties, Sobha, DLF, and Brigade fell over 2%.&nbsp;Britannia shares ended 4% lower on subdued June quarter (Q1 FY26) earnings. Divis Labs fell 3% and Bharat Forge slipped 2% after management shared a cautious outlook for the year ahead.Other earnings movers include Uno Minda (-1.7%), Asian Paints (+2%), and Pidilite Industries (+1.5%).&nbsp; BHEL fell 3%, and Hero Moto closed 2% lower ahead of Q1 earnings.NSDL shares surged 17% on its debut on Dalal Street.Stock Calls<a href="https://stocktwits.com/symbol/GODFRYPHLP.NSE">Godfrey Phillips</a> clocked in another session of gains, rising 10%. Analyst&nbsp;<a href="https://stocktwits.com/KavitaAgrawalCMTCFA">Kavita Agarwal</a> flagged it as a fundamentally strong stock, which is now showing a promising technical setup.&nbsp;On the weekly chart, it looks bullish, with room to rally towards ₹13,275, which represents 25% upside from current levels. She identified support at ₹9,860, indicating a 8% downside if the stock makes a lower low on the daily chart or fully retraces Wednesday’s candle. On the 75-minute chart, the Relative Strength Index (RSI) was overbought.&nbsp;Agarwal suggested setting an alert around 40–41 for RSI to catch a potential dip, which could offer a better re-entry point. She concluded that while a short-term dip was possible in Godfrey, it still warranted an inclusion on the ‘bullish watchlist’.<stembedurl>https://stocktwits.com/KavitaAgrawalCMTCFA/message/623898649</stembedurl><a href="https://stocktwits.com/WealthGURU0555">Yogesh Nirwan of Wealth Guru</a> recommended a buy on&nbsp;<a href="https://stocktwits.com/symbol/BAYERCROP.NSE">Bayer Crop</a> above ₹6,250 with a target price of ₹6,350, ₹6,450, and ₹6,800 for a stop loss of ₹6,200. He expects a price and volume breakout soon.<stembedurl>https://stocktwits.com/WealthGURU0555/message/623898251</stembedurl>Meanwhile, analyst&nbsp;<a href="https://stocktwits.com/investkaps">Kapil Aggarwal</a> has a buy call on&nbsp;<a href="https://stocktwits.com/symbol/LAURUSLABS.NSE">Laurus Labs</a> at ₹835-₹845 with a stop loss of ₹815 on a closing basis and a target price at ₹922.5.<stembedurl>https://stocktwits.com/investkaps/message/623896278</stembedurl>Markets: What Next?Analyst&nbsp;<a href="https://stocktwits.com/kyalashish">Ashish Kyal</a> noted that the&nbsp;<a href="https://stocktwits.com/symbol/NIFTY50.NSE">Nifty index</a> has been failing to generate momentum in any direction and testing a crucial zone multiple times, with 24,470 acting as a key support level. On the upside, a break above 24,680 is needed to gain some momentum. Kyal advised traders to avoid positional trades and focus on scalping this range.<stembedurl>https://stocktwits.com/kyalashish/message/623897818</stembedurl>Meanwhile,&nbsp;<a href="https://stocktwits.com/PROFIT_X_RESEARCH_SEBIRA">Varun Bhargav of ProfitXResearch</a> flagged that&nbsp;markets are flashing early warning signs, and that technology and pharmaceuticals&nbsp; stand out for potential sharp breakdowns ahead. He maintains a ‘sell on rise’ strategy on these two sectors.<stembedurl>https://stocktwits.com/PROFIT_X_RESEARCH_SEBIRA/message/623898355</stembedurl>Globally, European markets traded higher, while US stock futures indicate a positive start on Wall Street. Crude oil prices look poised to snap a four-day losing streak, as U.S. President Donald Trump’s continued threats to India to stop buying Russian oil raised concerns over supplies.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

An outside view of Bombay Stock Exchange on May 15, 2015 in Mumbai, India. (Photo by Aniruddha Chowdhury/Mint via Getty Images)

Trump’s tariff threats spooked investors. Analysts flagged early warning signals in tech and pharma sectors.

Current Price	3,313.70
Prev Close	3,327.00
Open	3,339.90
Dividend Yield	1.00%
50-Day Moving Average	3,444.36
Beta	N/A
Avg. Volume	118,066.32
PE Ratio	32.89

52-Week High	3,796.00
52-Week Low	2,445.80
Market Capitalization	414.43B
EPS (Annual)	84.53
Price to Book	8.55
Revenue Per Employee	4.11M

Feed

News

Sentiment

Fundamentals

Info

AJANTPHARM.NSE Fundamentals